Non-alcoholic fatty liver disease Trials in Richmond, United States
Conditions / Non-alcoholic fatty liver disease / Richmond, United States
Clinical trials for Non-alcoholic fatty liver disease investigate a range of treatment strategies and patient populations.
13 total trials for this combination
Showing top 10 of 13 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02077374 | A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases | COMPLETED | PHASE2 |
| NCT02784444 | A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH | COMPLETED | PHASE2 |
| NCT04197479 | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients | COMPLETED | PHASE3 |
| NCT03166735 | Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH | COMPLETED | PHASE2 |
| NCT03059446 | Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis | TERMINATED | PHASE2 |
| NCT04048876 | Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis | TERMINATED | PHASE2 |
| NCT05583344 | Phase 2b Study of GSK4532990 in Adults With NASH | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07221188 | A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH | RECRUITING | — |
| NCT07221227 | A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH | RECRUITING | — |
| NCT04951219 | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | ACTIVE_NOT_RECRUITING | PHASE3 |